BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dual-target Car-nk Cells readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dual-target Car-nk Cells\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07467863-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07467863)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Dual-Target CAR-NK Cells Directed Against MSLN\, EGFR\, or HER
 2 in Advanced NSCLC\nEstimated primary completion: 14 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dual-target-car-nk-cells#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07467
 863
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486089-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07486089)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: Dual-Target CAR-N
 K Cells for Advanced Breast Cancer (HER2+ and TNBC)\nEstimated primary com
 pletion: 14 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dual-target-car-nk-cells#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07486089
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480941-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Dual-target Car-nk Cells: Phase 1 readout est. (NCT07480941)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1.\nStudy: Dual-Targeting CAR-
 NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glio
 ma\nEstimated primary completion: 18 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07480941
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500220-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07500220)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: Dual-Target GPC3/
 B7-H3 CAR-NK Cells for Advanced HCC\nEstimated primary completion: 14 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dual-target-c
 ar-nk-cells#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07500220
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510802-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07510802)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: Dual-Target CAR-N
 K Cells for Advanced Breast Cancer HER2+ TNBC\nEstimated primary completio
 n: 14 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dua
 l-target-car-nk-cells#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07510802
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589543-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07589543)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: Dual-Target CAR-N
 K Cells in Recurrent or Refractory Epithelial Ovarian Cancer\nEstimated pr
 imary completion: 14 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dual-target-car-nk-cells#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07589543
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07617805-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07617805)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: EGFR/HER2 Dual-Ta
 rget CAR-NK Cells for Recurrent or Metastatic HNSCC\nEstimated primary com
 pletion: 14 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dual-target-car-nk-cells#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07617805
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641023-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07641023)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Dual-Target CAR-NK Cells Targeting MSLN\, EGFR\, or HER2 in Ad
 vanced NSCLC\nEstimated primary completion: 14 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07641023
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551336-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Dual-target Car-nk Cells: Phase 1 readout est. (NCT07551336)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1.\nStudy: Dual-Targeting CAR-
 NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma\nEst
 imated primary completion: 14 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07551336
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462650-2114@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20271221
DTEND;VALUE=DATE:20271222
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07462650)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2.\nStudy: Dual-Target CAR-N
 K Cells for Biomarker-Selected Advanced Colorectal Cancer\nEstimated prima
 ry completion: 21 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dual-target-car-nk-cells#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07462650
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
